• Free shipping for orders more than €200
  • Discreet packaging. Secure and confidential
  • 100% moneyback guarantee
  • No prescription required
Meridia (Sibutramine)

Meridia (Sibutramine)

Not in stock

Commercial Name: Meridia, Reductil
Principal Ingredient: Sibutramine
Utilization: Weight Loss and Obesity
Available Dosage: 10mg and 15mg

Category: Weight Loss
Delivery information
Description

Meridia is a drug used for the preservation remedy of sufferers with alimentary weight problems.

Meridia is produced within the form of tablets: tough gelatin, with a blue lid and a yellow (10 mg) or white (15 mg) color. it's miles categorized (relying on the dose) "10" or "15"; the contents of the tablets are without difficulty unfastened-flowing powder of just about white or white color. The composition of one capsule consists of sibutramine hydrochloride monohydrate - 10 mg, sodium lauryl sulfate, microcrystalline cellulose, lactose monohydrate, colloidal silicon dioxide, magnesium stearate, gelatin, titanium dioxide, and grey ink.

You need to no longer take this medicine if you have:

obesity with organic reasons;

Glaucoma;

severe eating disorders;

Neurological pathology (Tourette syndrome);

intellectual illness;

Meridia should be taken orally with out chewing and consuming a enough quantity of liquid (a glass of water), preferably within the morning. capsules can be blended with meals or taken on an empty belly. At the start of therapy often prescribed 10 mg of Meridia daily. within the absence of effectiveness, (a reduction in weight is less than 2 kg in step with month), or in the case of exact tolerability of the drug, it's miles viable to increase the each day dose to 15 mg.

For patients who are not attentive to receiving 15 mg of Meridia (the criterion is a weight reduction of much less than 4 kg in line with month), further therapy is not suitable. inside the case of skipping the drug, you need to take a double dose. For sufferers who do now not respond properly enough to therapy (weight loss of less than five% of the preliminary level within 3 months of therapy), the path must now not closing longer than three months.